## **Product** Data Sheet

## PARP-1/Proteasome-IN-1

Molecular Weight: 676.65

Target: Apoptosis; PARP; Proteasome

Pathway: Apoptosis; Cell Cycle/DNA Damage; Epigenetics; Metabolic Enzyme/Protease

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.

## **BIOLOGICAL ACTIVITY**

Description	PARP-1/Proteasome-IN-1 (compound 42i) is a dual PARP-1 and proteasome inhibitor with significant inhibitory effects on breast cancer. PARP-1/Proteasome-IN-1 can downregulate the expression of BRCA1 and RAD51 to inhibit homologous recombination repair function and induce apoptosis <sup>[1]</sup> .
IC <sub>50</sub> & Target	PARP-1, Proteasome <sup>[1]</sup>

## **REFERENCES**

[1]. He H et al. Design and synthesis of the first PARP-1 and proteasome dual inhibitors to treat breast cancer[J]. European Journal of Medicinal Chemistry, 2023: 115943.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA